Anixa Biosciences, Inc. (NASDAQ: ANIX), a US-based biotechnology company focused on the treatment and prevention of cancer, announced on Monday that the company along with its partner Moffitt Cancer Center has started treatment of the second patient in the ongoing clinical trial of the company's novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

This study, NCT05316129, a dose-escalation Phase 1 trial, is intended to assess safety and determine the maximum tolerated dose of follicle stimulating hormone receptor T-cells and to preliminarily evaluate clinical activity. It is being carried out at Moffitt Cancer Center. All subjects being enrolled in the trial have disease that is progressing and have failed around two, but often more, therapeutic interventions. The second subject received the same dose of engineered T-cells as the first subject in the trial, and the next (third) patient is likely to also receive the same dose. The successive three-patient cohort is likely to receive a higher dose of cells.

Dr Robert Wenham, the principal investigator of this trial at Moffitt Cancer Center, said, 'We are optimistic about the potential of this therapy to impact ovarian cancer patients who are out of all other options. Our goal is to increase enrolment at a responsible rate that enables us to understand the impact that our therapy is exhibiting.'